Signal from the log
BrainChild Bio
116 M$ · Series A · United States
BrainChild Bio développe des thérapies cellulaires CAR-T contre les tumeurs du système nerveux central, sous licence exclusive d'une technologie de Seattle Children's. Son candidat BCB-276 cible l'antigène B7-H3 et s'administre directement dans le liquide céphalorachidien, contre le gliome infiltrant du tronc cérébral, uniformément fatal chez l'enfant.
Article
Announced on , logged by the watch of 8 September 2026.
- Operation
- Funding round
- Announced amount
- 116 M$
- Stage
- Series A
- Country
- United States
What the log says
Editorial note, in French
Sujet traité. L'article donne les sources et la position de Bolus.
The investors
Led by Fonds familial privé et fondation, non divulgués , with Seattle Children's , WRF Capital
Provenance
Logged on 8 September 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Article The operation led to an article, with its sources checked one by one.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.